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Abstract
Background—Early diagnosis of infants infected with HIV (EID) and early initiation of 
treatment significantly reduces the rate of disease progression and mortality. One of the challenges 
to identification of HIV-1-infected infants is availability and/or access to quality molecular 
laboratory facilities which perform molecular virologic assays suitable for accurate identification 
of the HIV status of infants.
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Method—We conducted a joint site assessment and designed laboratories for the expansion of 
DNA polymerase chain reaction (PCR) testing based on dried blood spot (DBS) for EID in six 
regions of Ethiopia. Training of appropriate laboratory technologists and development of required 
documentation including standard operating procedures (SOPs) was carried out. The impact of the 
expansion of EID laboratories was assessed by the number of tests performed as well as the turn-
around time.
Results—DNA PCR for EID was introduced in 2008 in six regions. From April 2006 to April 
2008, a total of 2848 infants had been tested centrally at the Ethiopian Health and Nutrition 
Research Institute (EHNRI) in Addis Ababa, and which was then the only laboratory with the 
capability to perform EID; 546 (19.2%) of the samples were positive. By November 2010, EHNRI 
and the six laboratories had tested an additional 16 985 HIV-exposed infants, of which 1915 
(11.3%) were positive. The median turn-around time for test results was 14 days (range 14–21 
days).
Conclusion—Expansion of HIV DNA PCR testing facilities that can provide quality and 
reliable results is feasible in resource-limited settings. Regular supervision and monitoring for 
quality assurance of these laboratories is essential to maintain accuracy of testing.
Introduction
The Joint United Nations Programme on HIV and/or AIDS (UNAIDS) has estimated that in 
2009 between 230 000 and 510 000 children under the age of 15 years became infected with 
HIV worldwide, with over 90% of these new infections occurring in sub-Saharan Africa, 
and mainly through mother-to-child-transmission.1 Disease progression is aggressive in the 
first months of life in infants who acquired the infection in utero or around the time of 
delivery. If left untreated, almost half of these children will die before turning two years of 
age,2 and 75% by the age of five years. Most of these deaths in children with HIV could 
have been avoided through early infant diagnosis (EID) and provision of effective care and 
treatment. Interventions like the use of antiretroviral (ART) drugs by infected pregnant 
women, safe delivery practices and safe infant feeding have helped reduce the risk of 
transmission to infants (from 40% to 5–10%).3,4,5,6 Despite the availability of these life-
saving interventions, some exposed infants still get infected.
In 2003, ART services were initiated in Ethiopia and by 2005 free ART services started with 
the support of the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (GFATM).7 Furthermore, these services 
have been rolled out to regional health facilities at both hospital and health centre levels. 
The total number of patients on ART as of February 2010 was estimated at 179 183,8 
including 10 496 children. One of the major challenges to expansion of ART to children is 
limited or inadequate HIV diagnostic capacity.
Early identification of infants infected with HIV followed by prompt ART treatment can 
help reduce morbidity and mortality. The need for early initiation of treatment in infants 
infected with HIV was emphasised in a South African cohort study that showed that 55% 
and 85% of HIV-infected infants had their CD4 cell count reduced to less than 25% by three 
and six months after birth, respectively.9 Another study conducted in South Africa showed 
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that EID and early initiation of antiretroviral therapy helped to reduce mortality by 76% and 
HIV progression by 75%.10 Other studies have shown improved outcomes when early ART 
treatment is started in children.11,12 Thus, laboratory diagnosis plays a critical role in 
increasing access of HIV-exposed infants to testing, and eventual timely and effective 
treatment and care.
In adults, HIV is diagnosed by testing for the presence of antibodies to HIV in blood. In 
infants, antibody testing is inadequate, as persistent passively acquired maternal antibodies 
in the infant may yield false-positive results for up to 18 months or longer.13,14 It is 
important to provide accurate diagnostic services for identification of infants infected with 
HIV. Because of its high sensitivity and specificity, DNA polymerase chain reaction (PCR) 
has been widely used for diagnosis of HIV amongst exposed infants.15,16,17,18 The 
technology allows for PCR to be performed using a small spot from a dried blood spot 
(DBS) sample, as well as identification of infection from birth.19 Additionally, this 
molecular test has been successfully established in several resource-limited settings to 
increase access to treatment.20,21,22,23
Ethiopia has a tiered laboratory network, which is a hierarchical or ladder-like system with 
the national reference laboratory at the top followed by regional, referral and/or specialised 
hospital laboratories, then district and health centre laboratories. The tiered laboratory 
network reflects the structure through which health services are delivered to the population, 
and is under the coordination of the Ethiopian Health and Nutrition Research Institute 
(ENHRI), which is the technical arm of the Ministry of Health, with responsibility and 
oversight of the country’s public health laboratories. EHNRI has developed a 
comprehensive national laboratory master plan for integrated diseases. It has been used to 
coordinate and guide partners and stakeholders in the implementation of strategic laboratory 
objectives. The importance of the master plan in health system strengthening has previously 
been described.24
Until October 2007, EHNRI, which hosts Ethiopia’s national HIV reference laboratory, was 
the only facility performing DNA PCR for early infant diagnosis. EHNRI was able to serve 
the entire country with the implementation of a sample referral system which allowed for 
DBS to be transported and tested, and returned results to the different regions of the country. 
Ethiopia consists of about 1 127 127 square kilometers of land area, ranking it tenth in 
Africa in terms of land size.25 The challenge was to scale up laboratory capacity for DNA 
PCR in selected regions of Ethiopia in order to provide better and more adequate coverage.
Here we report on the experience of expansion of DNA PCR testing capabilities for early 
infant diagnosis to six different sites in Ethiopia with a substantial increase in the numbers 
of HIV-exposed infants tested.
Materials and methods
Project area
The project was carried out in Ethiopia, a country with a large land area situated in the horn 
of Africa and divided into nine administrative regions and two metropolitan city 
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administrations, Addis Ababa and Dire Dawa. HIV prevalence is estimated at 2.1%.26 There 
are an estimated 64 813 children under the age of 14 years living with HIV and/or AIDS, 75 
420 HIV positive pregnant women per year with an estimated 14 138 new infections 
occurring in children annually.26 The decentralisation of DNA PCR laboratories for EID 
was envisaged for six different sites to cover a greater geographic population.
Approach to project implementation
In 2006, the national implementation plan for EID of HIV infection was developed by 
EHNRI with the support of the US Centers for Disease Control and Prevention (CDC) and 
its partner, Columbia University’s International Center for AIDS Care and Treatment 
Program (ICAP). The DBS-based DNA PCR technology using the Amplicor HIV-1 Monitor 
v1.5 manual assay (Roche Diagnostics, Indianapolis Indiana, USA) was evaluated and EID 
services established at the national HIV reference laboratory of EHNRI. DNA PCR testing 
of DBS specimens at the national HIV reference laboratory started in April 2006. Because of 
the vastness of the country and the time taken to transport DBS samples to the only EID 
laboratory at EHNRI, there was the need to decentralise DNA PCR testing for EID to the 
regions. In 2007, a joint assessment between CDC Ethiopia, EHNRI and university partners 
was conducted on the facilities in the identified regions. Prior to this, a site assessment 
checklist was developed and used to assess potential sites. The joint site visit assessed state 
of infrastructure, personnel capacity, water, electricity and inventory, and provided 
recommendations. Technical inputs were provided in the design of the laboratories, 
including physical separations of pre-PCR and post-PCR rooms. University partners (John 
Hopkins, Columbia University and University of Washington) refurbished the laboratories 
in six regions for carrying out DNA PCR for EID.
CDC Ethiopia and EHNRI developed and purchased a comprehensive list of laboratory 
equipment, reagents and consumables. All sites had generators to serve as back-up for power 
outages. Standard operating procedures were developed and distributed to all six sites. 
Training materials were developed by EHNRI in collaboration with CDC Ethiopia and 
ICAP-Columbia University and used at each site. At least two laboratory technologists were 
trained per site on DNA PCR for EID using DBS. Following training, laboratory 
technologists were independently assessed for accurately performing the test. Two methods 
were used for assessing staff competency: the direct observational method was employed 
where the technologists were closely observed by a mentor as they performed assays 
independently per the SOPs and corrective actions provided where needed. Additionally, 
each technologist was provided with six DBS of known results (blinded DBS specimen) and 
asked to perform assays unsupervised. As part of maintaining quality of testing in each 
laboratory, yearly refresher trainings were conducted, followed by challenging trainees with 
blind DBS specimens. Additional trainings were provided for selected facilities based on the 
needs identified. Also, to control for quality of testing in the laboratory, any two or more 
consecutive Enzyme-linked immunosorbent assay (ELISA) wells samples that were positive 
were each repeated from the same DBS card sample on a different day. EHNRI served as a 
quality assurance laboratory for retesting the first 100 DBS specimens for each of the newly 
established sites.
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A comprehensive EID supply list was developed and laboratory technologists were trained 
in inventory management to ensure availability of supplies and thus avoid disruption of 
services as a result of shortage of one or several commodities. DNA PCR testing started at 
the Addis Ababa regional laboratory in April 2008, and at the Mekelle, Adama and Harar 
regional laboratories in May 2008, whilst at Bahir Dar and Hawassa it started in June 2008. 
Analysis of DBS tested for all sites was done up to November 2010. All six laboratories 
were enrolled in the CDC Atlanta external quality assessment programme to monitor 
laboratory performance for DNA PCR testing. Proficiency testing (PT) panels were sent 
three times per year to each testing site. Significant stages in the development and expansion 
of laboratory services for DNA PCR for EID are presented here (Figure 1).
In 2010, the postal service was introduced to transport DBS samples from referring sites to 
EID laboratories as well as delivering results back to referring sites. Prior to initiation of 
sample referral using the postal service, a memorandum of understanding was signed 
between the Ethiopian Postal Services Enterprise and EHNRI that included 565 facilities 
referring infant DBS samples. Postal workers were trained in transportation of DBS, filling 
in of DBS samples transport log forms indicating date and time of pick up and drop off from 
DBS referring sites and EID laboratories, respectively. Before the implementation of postal 
services in 2010, DBS samples and results were transported by an assigned facility staff 
member and/or university partners.
The laboratory turn-around time was established with the help of the EID laboratory 
logbook. Each DBS sample collected from an infant was accompanied by an EID request 
form from the referring site. The laboratory technologists recorded in the EID laboratory log 
book the date the DBS sample was received at the laboratory. When EID results are ready, 
the date the results are released or returned from the laboratory is recorded and signed for by 
a university partner or postal worker for the return of results to the referring site.
Results
Laboratory infrastructure and training
The six regional laboratories identified for expansion were strategically located around the 
country and included (1) Bahir Dar for the Amhara region, (2) Mekelle for Tigray region, 
(3) Hawassa for the Southern Nations, Nationalities and People’s (SNNP) region, (4) Adama 
for the Oromia region, (5) Harar for the Harari and (6) Somali regions and Addis Ababa for 
Addis Ababa city administration (Figure 2). By June 2008, all six identified regional 
reference laboratories had been completely renovated and well equipped with the 
instruments, software and laboratory consumables required for performing HIV-1 DNA 
PCR. The laboratory technologists were trained in laboratory biosafety, DBS specimen 
reception and/or rejection using criteria developed by CDC,27 accurately performing and 
interpreting test results, and reporting results back to referral sites. A total of 12 laboratory 
technologists (2 per site) were successfully trained and certified competent on-site for HIV-1 
DNA PCR testing. The laboratory technologists each scored 100% in their competency 
assessment when challenged with six blind specimens. That is, they correctly interpreted test 
kit controls, in-house controls, as well as all blind DBS specimens. The modest number of 
laboratory technologists trained was aimed at ensuring that testing services would be 
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minimally disrupted should one technologist be absent. Sample referral testing 
documentation and mechanisms to enable specimens to be transferred from referring sites to 
laboratories performing DNA PCR as well as reporting results back to referring sites were 
fully established.
Scale-up of laboratory services
Prior to April 2008, only prior to decentralisation the national HIV reference laboratory at 
EHNRI, located in Addis Ababa, was performing DNA PCR for EID (Figure 2). From 2006 
to April 2008, the national HIV reference laboratory had tested a total of 2848 infants’ DBS 
samples, of which 546 (19.2%) were positive and the results were sent back to referring sites 
(Figure 3). The DBS of HIV-exposed infants from prevention of mother-to-child 
transmission services and diagnostic specimens for clinical symptoms were tested. The 
results obtained for all laboratories that tested and provided infant DBS results up to 
November 2010 are shown in Figure 3. Of the 2209 tested for Bahir Dar, 278 (12.6%) were 
positive; 330 (7.5%) of 4369 were positive for Addis Ababa; 123 (10.1%) of 1222 were 
positive for Hawassa; 594 (13.1%) of 4525 positive for Adama; 117 (11.6%) of 1007 tested 
positive for Harar; and 214 (13.9%) of 1542 tested positive for Mekelle (Figure 3). 
Following decentralisation, EHNRI tested 2110 specimens, of which 259 (12.3%) were 
positive (Figure 3, EHNRI).
Although the number of specimens tested at EHNRI declined, EHNRI was still serving as a 
quality assurance laboratory for the newly established sites and testing specimens received 
from non-governmental organisation facilities, military and police hospitals, Afar, Gambella 
and Benishangul Gumuz regions. Of the total 19 832 DBS specimens tested from all testing 
sites between April 2006 and November 2010, 2461 (12.4%) were positive. At the end of 
2007, 26 clinical sites were collecting DBS samples. A total of 565 active facilities are 
currently sending infant samples to these testing laboratories. Together with the 
establishment of these new collection sites, there was a substantial increase in the number of 
samples tested following decentralisation of laboratory services from 2008 and each year 
thereafter (Figure 4).
Before decentralisation (April 2006 to March 2008), all the DBS samples were tested only at 
EHNRI laboratory and the median turn-around time was 13 days (range 1–59 days). After 
decentralisation (April 2008 to November 2010), the median turn-around time at EHNRI 
was 12 days (range 1–63 days). After decentralisation, the other six regional laboratories in 
the country had a median turn-around time of 14 days (range 14–21 days).
Quality of DBS DNA PCR testing
In addition to routinely conducting CDC Atlanta ’in-house’ DBS controls and test kit 
controls to validate performance of assays, all laboratories performed satisfactorily by 
scoring 100% in all PT sessions with the CDC PT panel programme. The quality assurance 
results on the first 100 DBS specimens for each of the newly established sites was 
concordance between results of EHNRI and those of the newly established laboratories. The 
repeat testing of any two or more consecutive positive samples showed concordance 
between the initial and the repeated test results.
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Because this was a programme impact assessment of expansion of DNA PCR laboratory for 
EID, no ethical approval was required.
Discussion
In this project, we have demonstrated the feasibility of laboratory expansion of DNA PCR 
testing for EID in a resource-limited setting. Following the expansion of testing facilities 
and the establishment of new collection sites, there was an increase in the number of infant 
DBS samples tested. Early diagnosis of HIV-infected infants can enable faster access to 
treatment and, in combination with other indicators, can contribute to monitoring the success 
in programmes for the prevention of mother-to-child transmission. HIV DNA PCR is 
recommended as the gold standard for virologic diagnosis of HIV in infants. However, 
issues with the high expense associated with establishing a virologic testing laboratory, 
technical complexities as well as the need to ensure good quality control and assurance in a 
resource-constrained setting have been raised. This has led to the establishment of a few 
facilities in centralised areas in resource-limited countries.
The commitment of the government and partners was key to the rapid and successful 
regional expansion of EID molecular technology. The expansion of the laboratory 
diagnostics services is in line with one of the strategic objectives of the master plan 
developed by EHNRI. This further demonstrates the importance of developing a master plan 
with clear strategic objectives that serves as a rallying and coordinating tool for 
implementing laboratory programmes amongst several laboratory stakeholders as well as 
evaluation of the implementation of the master plan. There was also the need to quickly 
establish good laboratory practice in these new facilities and to maintain quality of testing, 
considering the technical complexities of such molecular methods and the fact that infants 
may only have the opportunity for a single HIV test to determine their HIV infection status. 
Proper on-site training and competency assessment coupled with yearly refresher training 
and regular joint supportive site visits by EHNRI and partners have been important to 
maintaining quality testing. This has also been reflected in the satisfactory performance 
(100%) of all the facilities in CDC external quality assessment through PT panels. 
Following decentralisation of DNA PCR testing sites and scaling up of the number of 
collection sites, we observed a significant increase in the number of infants tested with DBS 
without an increase in the turn-around time from when specimens are received at the 
laboratory to return of results from the laboratory. With decentralisation, we observed that 
turn-around time of results to referring sites was a median of 14 days. This reflects a strong 
and functional sample and results referral system for expediting results. However, because 
of the low number of DBS specimens and the need for batch testing, it still took Harar and 
Hawassa up to three weeks to return results.
WHO guidelines recommend that HIV virologic tests be used to diagnose HIV infection in 
infants and children up to the age of 18 months.29 Additionally, the guidelines emphasise 
post-natal follow up of infants with unknown or uncertain HIV exposure in order to have 
their HIV exposure status ascertained and that HIV-infected infants be put immediately on 
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ART. Although 90% of children living with HIV acquired their infection through mother-to-
child transmission, relatively few have access to testing, treatment and care.30 There are 
several challenges to implementing early treatment for HIV-infected infants, including the 
diagnosis of HIV-infected infants, lack of rapid diagnostic capabilities for infants, weak 
sample referral testing systems, under-developed quality controls, limited trained personnel, 
inadequate clinical systems to follow up with patients, lack of integration amongst health 
services, and exogenous social factors. Addressing these challenges is likely to improve and 
maintain quality of testing and lead to increase uptake of HIV-infected infants to receiving 
treatment.
Direct comparison of the number of DBS tested at the different sites is difficult. The number 
of infants tested at the new facilities varied greatly, with Bahir Dar, Addis Ababa and 
Adama each having tested about two or more times as many as Hawassa or Harar. The 
observed difference could partly be explained by the population size and HIV prevalence of 
these regions, as well as the robustness of their PMTCT programme and clinical practices. 
Of the nine regions, Bahir Dar and Adama in Amhara and Oromiya regions, respectively, 
account for 23% and 36%, respectively, of the general population. Also, the HIV prevalence 
of the two regions is 2.7% and 1.5% for Amhara and Oromiya, respectively.26 The city of 
Addis Ababa site also showed an increase in DBS testing but accounts for only 3% of the 
population. However, the city of Addis Ababa has a relatively higher HIV prevalence of 
7.5%.26 By contrast, Hawassa in the SNNP region, which accounts for about 20% of the 
population, tested only 1222 DBS specimens. Together with the Harar and Mekelle sites, 
they tested fewer DBS specimens. These low numbers could be due to challenges with 
coordination of pediatric HIV care and treatment, PMTCT, and laboratory services in these 
regions.
Despite the successful scale-up of laboratory diagnostic services, significant challenges still 
persist and pose a problem for the provision of more comprehensive services for diagnosis 
and treatment of children. For example, the need for proper integration or linkages between 
programmes (e.g., laboratory and clinicians), identification of pregnant women, enrolling 
and scaling-up of the PMTCT programme. Furthermore, it has been difficult to determine 
the number of infants testing positive who received their test results and who received 
treatment and care. It is important to put in place a system for tracking DBS-positive results 
to ensure those infants receive treatment as well as for negative PCR results, to ensure that 
uninfected infants who continue to be exposed to HIV receive a final diagnosis. Similarly, 
improving the system of follow-up for infants and their caretakers is critical to avoid delays 
in initiating treatment.
The rapid scale-up of laboratory services to perform DNA PCR for EID and treatment of 
infected children is an essential component to child survival and successful outcomes of 
PMTCT programmes. Proper joint planning, implementation, commitment and coordination 
involving stakeholders have made rapid scale-up possible. Continuous monitoring of these 
new sites is essential, and adhering to all aspects of quality would ensure that accurate 
results are provided for prompt intervention.
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Milestones in expansion of laboratory services for early HIV infant diagnosis in Ethiopia.
EID, early HIV infant diagnosis; DBS, dried blood spot; PCR, polymerase chain reaction; 
CDC, Centers for Disease Control an Prevention.
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Regionalisation of early infant diagnosis
Rollout of DNA polymerase chain reaction facilities for early infant diagnosis to regions in 
Ethiopia. Circle in blue denotes national HIV reference laboratory at the Ethiopian Health 
and Nutrition Research Institute in Addis Ababa where early HIV infant diagnosis (EID) 
started in 2006. Crosses in blue denote location of new sites with names in red and their 
regions (in black) where EID testing occurred following rollout in 2008. Harar site is for 
Harari region. SNNPR represents Southern Nations, Nationalities and People’s region.
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Proportion of dried blood spot (DBS) tested positive by site.
Impact of expansion of DNA polymerase chain reaction (PCR) laboratory for early infant 
diagnosis of HIV-1. Dagger (†) denotes the only site the Ethiopian Health and Nutrition 
Research Institute (EHNRI) before rollout to new sites in the regions. The total number of 
DBS specimens tested and the number positive for each site is shown at the top of each bar 
for that site. For instance, EHNRI† had tested 2848 DBS specimens with 546 positives 
before decentralisation and 2110 DBS with 259 positives after decentralisation.
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The total number of dried blood spot (DBS) specimens tested and the number positive by 
year between 2006 and 2010.
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